Juvenescence is the U.K. firm trying to increase human longevity. The startup recently received a $10 million investment from billionaire Mike Cannon-Brookes, the cofounder of Australian software giant Atlassian.
The startup is aiming to extend the average human life span, today, it’s around 72 years. Billionaires are investing heavily in a handful of life science startups hoping to make people live longer.
Instead of working towards one single cure all for a longer life, the startup aims to build a “longevity ecosystem”, a portfolio of interlinked companies working on therapies and treatments helping people to live longer, healthier lives.
The Juvenescence team currently consists of 20 scientists, drug developers, AI specialists, and financial experts, coordinating the efforts of its portfolio. The firm is working towards new treatments for cancer, diabetes, neurodegenerative disorders and heart disease.
To date, Juvenescence has invested in 15 companies, including California-based AgeX Therapeutics and Fox Bio. Both companies are working on therapies that can improve old human tissue.
“We have recruited a group of sophisticated shareholders from around the world to further our common mission of improving human healthy lifespan,” Jim Mellon, chair of Juvenescence, said in a statement.